Medicinova, Inc. · NASDAQ:MNOV
Medicinova — Investor Presentation (May 2026)
25 slides from Medicinova's investor presentation, May 2026
Slide 1: MediciNova Investor Presentation
MediciNova Investor Presentation May 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements in this presentation that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding M
Slide 3: Investment Highlights
Investment Highlights ✓ Core ALS Value Driver: Late-stage ALS opportunity with enrollment completed in the registrational Phase 2b/3 COMBAT-ALS trial evaluating MN-166 (ibudilast; oral and IV), targeting a $3+ billion orphan market with limited effective treatment options ✓ Well-established safety a
Slide 4: Our Unique Model – Focused, Capital Efficient, De-Risked
Our Unique Model – Focused, Capital Efficient, De-Risked ASCVD/Dyslipidemia CORE FOCUS NON-CORE PROGRAMS ALS NAFLD Self-funded Externally funded High value driver Multiple shots on goal Oncology Clear regulatory path Partnered or grant-driven Acute Lung Commercial Opportunity Upside optionality Inju
Slide 5: MediciNova's Pipeline
MediciNova’s Pipeline Topline 4Q 2026 Topline 3Q 2026
Slide 6: Academic & Government Partnered Programs
Academic & Government Partnered Programs • All partnered programs fully funded by government agencies and run by academic researchers from reputable institutions in US, UK, Australia, and Canada • Upon trial completion, MediciNova has full rights to regulatory pathway and exclusive rights to commerc
Slide 7: MN-166: ALS
MediciNova’s CORE ALS Program MN-166: ALS Ibudilast 7
Slide 8: MN-166 Overview
MN-166 Overview CODE MN-166 Description Small Molecule Chemical Name Ibudilast Oral Administrate Route I.V. injection CNS-penetrant compound (Exhibits robust CNS bioavailability) Multiple MOAs MIF (macrophage inhibitory factor) inhibitor PDE (phosphodiesterase) 3, 4, 10 and 11 inhibitor Mechanism of
Slide 9: MN-166's Unique Mechanism in ALS
MN-166’s Unique Mechanism in ALS Neuroinflammation Reduction: • MIF inhibition, PDEs inhibition, and TLR4 inhibition reduce pro-inflammatory signaling. • Attenuate glial cell activation, which is a major contributor to neurodegeneration in ALS. Neuroprotection: • By reducing neuroinflammation and en
Slide 10: Positive outcome from first Phase 2a ALS study (MN-166-ALS-1201)
Positive outcome from first Phase 2a ALS study (MN-166-ALS-1201) Study Summary • Single-center (PI: Dr. Brooks, Carolina Neuromuscular ALS MDA Center), R(1:2), PCT, DB followed by OLE • Target ALS patients (ALS history ~ 5 years), on Riluzole treatment • Treatment: 60 mg/day MN-166 or Placebo X 6 mo
Slide 11: ALS: Unmet Need & Market Opportunity
ALS: Unmet Need & Market Opportunity A large, underserved orphan market where existing therapies have failed to meaningfully alter disease progression, creating a significant opportunity for differentiated, durable treatments • ~30,000 people in the U.S. living with ALS with an average life expectan
Slide 12: Ongoing Phase 2b/3 ALS study (COMBAT-ALS / MN-166-ALS-2301)
Ongoing Phase 2b/3 ALS study (COMBAT-ALS / MN-166-ALS-2301) Study Sites : Multi-centers in US and Canada Study Design : R (1:1), PCT, DB study followed by OLE Target Patients: ALS (ALS history within 18 mo ) Dose : 100mg/day or placebo Treatment Duration : 12-mo DB, 6-mo OLE Size: N=230 (randomize)
Slide 13: Ongoing Phase 2b/3 ALS study - Baseline Characteristics (n=234)
Ongoing Phase 2b/3 ALS study - Baseline Characteristics (n=234) Major Inclusion Criteria • Male or female subjects ages 18 to 80 years, inclusive; • Diagnosis of familial or sporadic ALS as defined by the El Escorial-Revised (2000) research diagnostic criteria for ALS [clinically definite, clinicall
Slide 14: MN-166 Competitive Differentiation in the ALS Treatment Landscape
MN-166 Competitive Differentiation in the ALS Treatment Landscape Target Population Administration Safety Efficacy Regulatory Status Price per Year Differentiation 30+ years commercial Multi-target therapy; NIH Broad Oral 2026 data readout Phase 3 - activity outside the US EAP program MN-166 Standar
Slide 15: Ongoing NIH funding Expand Access ALS study (SEA-NOBI-ALS)
Ongoing NIH funding Expand Access ALS study (SEA-NOBI-ALS) Sponsor : NIH NINDS (National Institute of Neurological Disorders and Strokes ) Funding Amount : $ 22M Lead PI : Mayo Clinic Dr. Oskarsson Study Sites : Multi-centers in US (approx. 20 sites) Study Design: Open-Label study Target Patients: L
Slide 16: MN-001, ASCVD/Dyslipidemia and NAFLD/MAFLD
MN-001, ASCVD/Dyslipidemia and NAFLD/MAFLD Tipelukast 16
Slide 17: MN-001 Overview
MN-001 Overview CODE MN-001 Description Small Molecule Chemical Name Tipelukast Administrate Route Oral Mechanism of Action Multiple MOA Leukotriene & 5-lipoxygenase (5-LO) pathway inhibitor PDE (phosphodiesterase) 3,4 inhibitor leukotriene receptor antagonism Clinical effect Anti-inflammation, anti
Slide 18: Positive outcome from first Phase 2 NAFLD/NASH + HyperTG study
Positive outcome from first Phase 2 NAFLD/ NASH + HyperTG study (MN- 001-NATG-201) Study Summary • Multi-center , Open-Label study in US • NAFLD/NASH patients with Hyper TG • Treatment : 250 mg/day x 4 weeks followed by 500 mg/day x 8 weeks • Total 19 patients enrolled Serum TG level (mg/dL) Serum H
Slide 19: Ongoing Phase 2 HyperTG + T2DM + NAFLD study (MN-001-NATG-202)
Ongoing Phase 2 HyperTG + T2DM + NAFLD study (MN-001-NATG-202) Study Sites : 2 centers in US Study Design : R (1:1), PCT, DB study • Jubilee Clinical Research Center o PI: Dr. Shin • South Texas Research Institute o PI: Dr. Patil Target Patients : HyperTG + T2DM+ NAFLD Dose : 500mg/day or placebo Tr
Slide 20: Near-Term Catalysts
Near-Term Catalysts • Achieved target patient enrollment with MN-001- NATG-202 → expect top line data Q3 2026 • Achieved patient enrollment goal (n=234) with COMBAT ALS in Sep 2025→ expect top line data by end of 2026; Orphan Drug Designation and Fast Track • Planning discussions with FDA • Particip
Slide 21: Financial Overview
Financial Overview Dual-listed Future $27.3 M Cash (NASDAQ & partnership position sufficient Tokyo Stock deals could to reach ALS Exchange) further extend milestones runway Phase 2 Metabolic Readout Annual burn Zero Expected Q3 2026 ALS Phase 2b/3 ~US$12-13M Debt Readout Expected EOY 2026 21 © Medic
Slide 22: Why Invest in MediciNova?
Why Invest in MediciNova? MediciNova is redefining ALS therapeutics with a uniquely capital-efficient model and multiple paths to value. We’re committed to delivering breakthroughs for patients — and significant returns for investors. • ALS core program with Orphan Drug Designation and Fast Track st
Slide 23: Management
Management Yuichi Iwaki, M.D., Ph.D., Founder, CEO, President University of Southern California Keck School of Medicine, Nihon University School of Medicine, Kyushu University and Toho University, School of Medicine Kazuko Matsuda, M.D., Ph.D., M.P.H., Chief Medical Officer University of Southern Ca
Slide 24: Board of Directors
Board of Directors Hideki Nagao 40+ years of experience in finance and corporate law with financial institutions in Japan. Carolyn Beaver Director of MaxLinear, Inc, Organovo Holdings, Inc., various positions at Sequenom Inc., Beckman Coulter, Inc., Commerce National Bank, Newport Beach, California
Slide 25: Thank you!
CONTACT: Thank you! Yuichi Iwaki, MD, PhD David H. Crean, PhD CEO/President Chief Business Officer iwaki@medicinova.com crean@medicinova.com 25 © MediciNova, Inc.